Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Ovarian Neoplasms

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 93 articles:
HTML format



Single Articles


    September 2022
  1. CHEN YA, Lu CY, Cheng WF, Kuo KT, et al
    An experimental model for ovarian cancer: propagation of ovarian cancer initiating cells and generation of ovarian cancer organoids.
    BMC Cancer. 2022;22:967.
    PubMed     Abstract available


  2. KIM SI, Lee HC, Yoon HK, Kim HS, et al
    Impact of hemodynamic instability during cytoreductive surgery on survival in high-grade serous ovarian carcinoma.
    BMC Cancer. 2022;22:965.
    PubMed     Abstract available


    August 2022
  3. YIN J, Wen Y, Zeng J, Zhang Y, et al
    CDC50A might be a novel biomarker of epithelial ovarian cancer-initiating cells.
    BMC Cancer. 2022;22:903.
    PubMed     Abstract available


  4. ZHANG Y, Wu H, Yu Z, Li L, et al
    Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients.
    BMC Cancer. 2022;22:842.
    PubMed     Abstract available


    July 2022
  5. BRAICU EI, Krause CL, Torsten U, Mecke H, et al
    HE4 as a serum biomarker for the diagnosis of pelvic masses: a prospective, multicenter study in 965 patients.
    BMC Cancer. 2022;22:831.
    PubMed     Abstract available


  6. FANG DD, Tao R, Wang G, Li Y, et al
    Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
    BMC Cancer. 2022;22:752.
    PubMed     Abstract available


  7. KENNEDY F, Shearsmith L, Holmes M, Rogers Z, et al
    Electronic patient-reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study.
    BMC Cancer. 2022;22:726.
    PubMed     Abstract available


    June 2022
  8. SOHN EJ
    PIK3R3, a regulatory subunit of PI3K, modulates ovarian cancer stem cells and ovarian cancer development and progression by integrative analysis.
    BMC Cancer. 2022;22:708.
    PubMed     Abstract available


  9. LIM H, Bang SH, Kim Y, Cho SH, et al
    Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study.
    BMC Cancer. 2022;22:703.
    PubMed     Abstract available


  10. BORDE J, Laitman Y, Blumcke B, Niederacher D, et al
    Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
    BMC Cancer. 2022;22:706.
    PubMed     Abstract available


  11. GOU R, Zheng M, Hu Y, Gao L, et al
    Identification and clinical validation of NUSAP1 as a novel prognostic biomarker in ovarian cancer.
    BMC Cancer. 2022;22:690.
    PubMed     Abstract available


  12. ZHU S, Bao H, Zhang MC, Liu H, et al
    KAZN as a diagnostic marker in ovarian cancer: a comprehensive analysis based on microarray, mRNA-sequencing, and methylation data.
    BMC Cancer. 2022;22:662.
    PubMed     Abstract available


  13. SONG Y, Qu H
    Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    BMC Cancer. 2022;22:633.
    PubMed     Abstract available


  14. XU Q, Liu Y, Wang S, Wang J, et al
    Interfering with the expression of EEF1D gene enhances the sensitivity of ovarian cancer cells to cisplatin.
    BMC Cancer. 2022;22:628.
    PubMed     Abstract available


  15. YART L, Bastida-Ruiz D, Allard M, Dietrich PY, et al
    Linking unfolded protein response to ovarian cancer cell fusion.
    BMC Cancer. 2022;22:622.
    PubMed     Abstract available


    May 2022
  16. LEIBOWITZ BD, Dougherty BV, Bell JSK, Kapilivsky J, et al
    Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
    BMC Cancer. 2022;22:587.
    PubMed     Abstract available


  17. WEN H, Feng Z, Ma Y, Liu R, et al
    Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
    BMC Cancer. 2022;22:550.
    PubMed     Abstract available


  18. HU X, Zhang J, Cao Y
    Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study.
    BMC Cancer. 2022;22:544.
    PubMed     Abstract available


  19. MCLAUGHLIN PMJ, Klar M, Zwimpfer TA, Dutilh G, et al
    Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.
    BMC Cancer. 2022;22:508.
    PubMed     Abstract available


  20. GLASS EB, Hoover AA, Bullock KK, Madden MZ, et al
    Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer.
    BMC Cancer. 2022;22:497.
    PubMed     Abstract available


    April 2022
  21. SATO S, Matsushita H, Shintani D, Kobayashi Y, et al
    Association between effector-type regulatory T cells and immune checkpoint expression on CD8(+) T cells in malignant ascites from epithelial ovarian cancer.
    BMC Cancer. 2022;22:437.
    PubMed     Abstract available


  22. BOWERS RR, Andrade MF, Jones CM, White-Gilbertson S, et al
    Autophagy modulating therapeutics inhibit ovarian cancer colony generation by polyploid giant cancer cells (PGCCs).
    BMC Cancer. 2022;22:410.
    PubMed     Abstract available


  23. AYYAGARI V, Li M, Pasman Z, Wang X, et al
    Assessment of the diagnostic and prognostic relevance of ACAT1 and CE levels in plasma, peritoneal fluid and tumor tissue of epithelial ovarian cancer patients - a pilot study.
    BMC Cancer. 2022;22:387.
    PubMed     Abstract available


  24. WALTHER F, Berther JL, Lalos A, Ramser M, et al
    High ratio of pCXCR4/CXCR4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy.
    BMC Cancer. 2022;22:376.
    PubMed     Abstract available


  25. KONO-SATO T, Miyai K, Yamagishi Y, Miyamoto M, et al
    Intraepithelial lymphocytes are indicators of better prognosis in surgically resected endometrioid-type endometrial carcinomas at early and advanced stages.
    BMC Cancer. 2022;22:361.
    PubMed     Abstract available


    March 2022
  26. SUH YJ, Lee B, Kim K, Jeong Y, et al
    Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
    BMC Cancer. 2022;22:346.
    PubMed     Abstract available


  27. XIAOHUA ZHU, Xie Y, Huang W, Chen Z, et al
    NAP1L1 promotes tumor proliferation through HDGF/C-JUN signaling in ovarian cancer.
    BMC Cancer. 2022;22:339.
    PubMed     Abstract available


  28. WANG W, Wang T, Liu Z, He J, et al
    Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China.
    BMC Cancer. 2022;22:266.
    PubMed     Abstract available


  29. BINDER PS, Hashim YM, Cripe J, Buchanan T, et al
    The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer.
    BMC Cancer. 2022;22:263.
    PubMed     Abstract available


  30. SONG Z, Wang Y, Zhou Y, Zhang D, et al
    Nomograms to predict the prognosis in malignant ovarian germ cell tumors: a large cohort study.
    BMC Cancer. 2022;22:257.
    PubMed     Abstract available


    February 2022
  31. ELBIAD O, Laraqui A, El Boukhrissi F, Mounjid C, et al
    Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    BMC Cancer. 2022;22:208.
    PubMed     Abstract available


  32. SUMINOKURA J, Miyamoto M, Yoshikawa T, Kouta H, et al
    Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis.
    BMC Cancer. 2022;22:176.
    PubMed     Abstract available


  33. SHARMA AL, Meitei PM, Machathoibi TC, Singh NT, et al
    Ovarian cancer G protein-coupled receptor 1 inhibits A549 cells migration through casein kinase 2alpha intronless gene and neutral endopeptidase.
    BMC Cancer. 2022;22:143.
    PubMed     Abstract available


    January 2022
  34. LI B, Lou G, Zhang J, Cao N, et al
    Repression of lncRNA PART1 attenuates ovarian cancer cell viability, migration and invasion through the miR-503-5p/FOXK1 axis.
    BMC Cancer. 2022;22:124.
    PubMed     Abstract available


  35. WONG-BROWN MW, van der Westhuizen A, Bowden NA
    Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.
    BMC Cancer. 2022;22:100.
    PubMed     Abstract available


  36. CHEN W, Shan B, Zhou S, Yang H, et al
    Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.
    BMC Cancer. 2022;22:92.
    PubMed     Abstract available


  37. LI Y, Gong X, Hu T, Chen Y, et al
    Two novel prognostic models for ovarian cancer respectively based on ferroptosis and necroptosis.
    BMC Cancer. 2022;22:74.
    PubMed     Abstract available


  38. SATO M, Sato S, Shintani D, Hanaoka M, et al
    Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma.
    BMC Cancer. 2022;22:59.
    PubMed     Abstract available


  39. PARK SJ, Chang SJ, Suh DH, Kong TW, et al
    A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer.
    BMC Cancer. 2022;22:28.
    PubMed     Abstract available


  40. AGHA N, Alshamsan B, Al-Farsi S, Ateya HA, et al
    Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women.
    BMC Cancer. 2022;22:18.
    PubMed     Abstract available


  41. NING L, Lang J, Wu L
    Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer.
    BMC Cancer. 2022;22:6.
    PubMed     Abstract available


  42. LAI Z, Brosnan M, Sokol ES, Xie M, et al
    Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.
    BMC Cancer. 2022;22:13.
    PubMed     Abstract available


    December 2021
  43. AZRIBI F, Abdou E, Dawoud E, Ashour M, et al
    Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study.
    BMC Cancer. 2021;21:1350.
    PubMed     Abstract available


    October 2021
  44. CREEDEN JF, Nanavaty NS, Einloth KR, Gillman CE, et al
    Homologous recombination proficiency in ovarian and breast cancer patients.
    BMC Cancer. 2021;21:1154.
    PubMed     Abstract available


  45. GERNIER F, Ahmed-Lecheheb D, Pautier P, Floquet A, et al
    "Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovaria
    BMC Cancer. 2021;21:1147.
    PubMed     Abstract available


  46. HU X, Li D, Liang Z, Liao Y, et al
    Indirect comparison of the diagnostic performance of (18)F-FDG PET/CT and MRI in differentiating benign and malignant ovarian or adnexal tumors: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:1080.
    PubMed     Abstract available


    September 2021
  47. HASENBURG A, Eichkorn D, Vosshagen F, Obermayr E, et al
    Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial.
    BMC Cancer. 2021;21:1037.
    PubMed     Abstract available


  48. QIAO ZW, Jiang Y, Wang L, Wang L, et al
    LINC00852 promotes the proliferation and invasion of ovarian cancer cells by competitively binding with miR-140-3p to regulate AGTR1 expression.
    BMC Cancer. 2021;21:1004.
    PubMed     Abstract available


  49. AMAYA C, Luo S, Baigorri J, Baucells R, et al
    Exposure to low intensity ultrasound removes paclitaxel cytotoxicity in breast and ovarian cancer cells.
    BMC Cancer. 2021;21:981.
    PubMed     Abstract available


    August 2021
  50. SU R, Jin C, Zhou L, Cao Y, et al
    Construction of a ceRNA network of hub genes affecting immune infiltration in ovarian cancer identified by WGCNA.
    BMC Cancer. 2021;21:970.
    PubMed     Abstract available


    July 2021
  51. WANG H, Fu Y
    NR1D1 suppressed the growth of ovarian cancer by abrogating the JAK/STAT3 signaling pathway.
    BMC Cancer. 2021;21:871.
    PubMed     Abstract available


  52. YAN X, Zhang S, Jia J, Yang J, et al
    Exploring the malnutrition status and impact of total parenteral nutrition on the outcome of patients with advanced stage ovarian cancer.
    BMC Cancer. 2021;21:799.
    PubMed     Abstract available


  53. WANG W, Zou L, Wang T, Liu Z, et al
    Treatment optimization of pelvic external beam radiation and/or vaginal brachytherapy for patients with stage I to II high-risk Endometrioid adenocarcinoma: a retrospective multi-institutional analysis.
    BMC Cancer. 2021;21:774.
    PubMed     Abstract available


  54. LI Y, Jaiswal SK, Kaur R, Alsaadi D, et al
    Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer.
    BMC Cancer. 2021;21:768.
    PubMed     Abstract available


    June 2021
  55. HE X, Wei L, Li R, Jing S, et al
    Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study.
    BMC Cancer. 2021;21:738.
    PubMed     Abstract available


  56. KOTNIK U, Peterlin B, Lovrecic L
    Identification of women at risk for hereditary breast and ovarian cancer in a sample of 1000 Slovenian women: a comparison of guidelines.
    BMC Cancer. 2021;21:665.
    PubMed     Abstract available


    May 2021
  57. HAWARDEN A, Russell B, Gee ME, Kayali F, et al
    Correction to: Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study.
    BMC Cancer. 2021;21:614.
    PubMed    


  58. WANG B, Wang S, Ren W
    Development and validation of a nomogram to predict survival outcome among epithelial ovarian cancer patients with site-distant metastases: a population-based study.
    BMC Cancer. 2021;21:609.
    PubMed     Abstract available


  59. PIROLLI R, de Alencar VTL, Estati FL, Ribeiro ARG, et al
    Comparison of dose-dense vs. 3-weekly paclitaxel and carboplatin in the first-line treatment of ovarian cancer in a propensity score-matched cohort.
    BMC Cancer. 2021;21:525.
    PubMed     Abstract available


  60. LAPKE N, Chen CH, Chang TC, Chao A, et al
    Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
    BMC Cancer. 2021;21:499.
    PubMed     Abstract available


  61. WANG C, Hu K, Deng L, He W, et al
    Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.
    BMC Cancer. 2021;21:491.
    PubMed     Abstract available


  62. SHIN W, Park SY, Kang S, Lim MC, et al
    How to manage synchronous endometrial and ovarian cancer patients?
    BMC Cancer. 2021;21:489.
    PubMed     Abstract available


    April 2021
  63. LEANDERSSON P, Hogberg T, Dickman PW, Malander S, et al
    Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960-2014: A population-based cohort study.
    BMC Cancer. 2021;21:465.
    PubMed     Abstract available


  64. XUE B, Li S, Jin X, Liu L, et al
    Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
    BMC Cancer. 2021;21:452.
    PubMed     Abstract available


  65. LI S, Yang T, Xiang Y, Li X, et al
    Clinical characteristics and survival outcomes of malignant struma ovarii confined to the ovary.
    BMC Cancer. 2021;21:383.
    PubMed     Abstract available


  66. HAWARDEN A, Russell B, Gee ME, Skayali F, et al
    Factors determining ultra-short-term survival and the commencement of active treatment in high-grade serous ovarian cancer: a case comparison study.
    BMC Cancer. 2021;21:378.
    PubMed     Abstract available


    March 2021
  67. ZHU C, Zhu J, Qian L, Liu H, et al
    Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
    BMC Cancer. 2021;21:322.
    PubMed     Abstract available


  68. TOPNO R, Singh I, Kumar M, Agarwal P, et al
    Integrated bioinformatic analysis identifies UBE2Q1 as a potential prognostic marker for high grade serous ovarian cancer.
    BMC Cancer. 2021;21:220.
    PubMed     Abstract available


    February 2021
  69. GUO J, Satoh K, Tabata S, Mori M, et al
    Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells.
    BMC Cancer. 2021;21:174.
    PubMed     Abstract available


  70. ZHANG H, Zhang K, Xu Z, Chen Z, et al
    MicroRNA-545 suppresses progression of ovarian cancer through mediating PLK1 expression by a direct binding and an indirect regulation involving KDM4B-mediated demethylation.
    BMC Cancer. 2021;21:163.
    PubMed     Abstract available


    January 2021
  71. LI J, Yue H, Yu H, Lu X, et al
    Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer.
    BMC Cancer. 2021;21:67.
    PubMed     Abstract available


  72. YAN S, Fang J, Chen Y, Xie Y, et al
    Correction to: Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.
    BMC Cancer. 2021;21:55.
    PubMed    


  73. GRIMES MM, Kenney SR, Dominguez DR, Brayer KJ, et al
    The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo.
    BMC Cancer. 2021;21:40.
    PubMed     Abstract available


  74. KAYAHASHI K, Mizumoto Y, Matsuoka A, Obata T, et al
    Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
    BMC Cancer. 2021;21:32.
    PubMed     Abstract available


    December 2020
  75. KIM SI, Hwang WY, Lee M, Kim HS, et al
    Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles.
    BMC Cancer. 2020;20:1199.
    PubMed     Abstract available


  76. YAN S, Fang J, Chen Y, Xie Y, et al
    Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer.
    BMC Cancer. 2020;20:1205.
    PubMed     Abstract available


    November 2020
  77. TSUTSUMI M, Miura H, Inagaki H, Shinkai Y, et al
    An aggressive systemic mastocytosis preceded by ovarian dysgerminoma.
    BMC Cancer. 2020;20:1162.
    PubMed     Abstract available


    October 2020
  78. LI M, Cheng X, Rong R, Gao Y, et al
    High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
    BMC Cancer. 2020;20:1032.
    PubMed     Abstract available


  79. SONG L, Tang Z, Peng C, Yang Y, et al
    Cell type-specific genotoxicity in estrogen-exposed ovarian and fallopian epithelium.
    BMC Cancer. 2020;20:1020.
    PubMed     Abstract available


  80. JOHANSEN G, Dahm-Kahler P, Staf C, Floter Radestad A, et al
    A Swedish Nationwide prospective study of oncological and reproductive outcome following fertility-sparing surgery for treatment of early stage epithelial ovarian cancer in young women.
    BMC Cancer. 2020;20:1009.
    PubMed     Abstract available


  81. FOGG KC, Miller AE, Li Y, Flanigan W, et al
    Ovarian cancer cells direct monocyte differentiation through a non-canonical pathway.
    BMC Cancer. 2020;20:1008.
    PubMed     Abstract available


  82. STOCKLEY J, Akhand R, Kennedy A, Nyberg C, et al
    Detection of MCM5 as a novel non-invasive aid for the diagnosis of endometrial and ovarian tumours.
    BMC Cancer. 2020;20:1000.
    PubMed     Abstract available


  83. HOOVER AA, Hufnagel DH, Harris W, Bullock K, et al
    Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer.
    BMC Cancer. 2020;20:970.
    PubMed     Abstract available


  84. ESCALONA RM, Bilandzic M, Western P, Kadife E, et al
    TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
    BMC Cancer. 2020;20:960.
    PubMed     Abstract available


    September 2020
  85. HU J, Jiao X, Zhu L, Guo H, et al
    Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma.
    BMC Cancer. 2020;20:938.
    PubMed     Abstract available


  86. ZHANG D, Chen X, Xia H, Wang L, et al
    Promotion of the occurrence of endometrioid carcinoma by S100 calcium binding protein P.
    BMC Cancer. 2020;20:845.
    PubMed     Abstract available


    August 2020
  87. LI N, Gou J, Li L, Ming X, et al
    Staging procedures fail to benefit women with borderline ovarian tumours who want to preserve fertility: a retrospective analysis of 448 cases.
    BMC Cancer. 2020;20:769.
    PubMed     Abstract available


    June 2020
  88. ITO M, Kodaira T, Koide Y, Okuda T, et al
    Role of high-dose salvage radiotherapy for oligometastases of the localised abdominal/pelvic lymph nodes: a retrospective study.
    BMC Cancer. 2020;20:540.
    PubMed     Abstract available


    May 2020
  89. VAN DER MERWE NC, Oosthuizen J, Theron M, Chong G, et al
    The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer.
    BMC Cancer. 2020;20:391.
    PubMed     Abstract available


  90. PARK SJ, Shim SH, Ji YI, Kwon SH, et al
    Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial.
    BMC Cancer. 2020;20:385.
    PubMed     Abstract available


    April 2020
  91. TANABE Y, Shiraishi S, Hashimoto K, Ikeda K, et al
    Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
    BMC Cancer. 2020;20:325.
    PubMed     Abstract available


    March 2020
  92. PRZYBYTKOWSKI E, Davis T, Hosny A, Eismann J, et al
    An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    BMC Cancer. 2020;20:197.
    PubMed     Abstract available


  93. ONWUKA JU, Okekunle AP, Olutola OM, Akpa OM, et al
    Lipid profile and risk of ovarian tumours: a meta-analysis.
    BMC Cancer. 2020;20:200.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: